Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06947044

Biomarkers in Patients With Anemia-Induced Thrombocytopenic Bleeding

Led by Donald Arnold · Updated on 2025-04-27

60

Participants Needed

1

Research Sites

81 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This pilot study aims to gather preliminary evidence on how different hemoglobin levels impact blood biomarkers related to bleeding. The feasibility of conducting a future larger clinical trial will also be assessed. Red blood cell transfusions are part of the standard of care for patients with leukemia. This study evaluates two transfusion strategies: one that maintains hemoglobin levels above the standard-of-care threshold, reflecting current routine practice; and another that maintains hemoglobin levels above 110 g/L, which is closer to the normal hemoglobin range. The normal hemoglobin range is 120-160 g/L for females and 140-180 g/L for males. Raising hemoglobin levels closer to normal values may reduce bleeding risk.

CONDITIONS

Official Title

Biomarkers in Patients With Anemia-Induced Thrombocytopenic Bleeding

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years old or older
  • Currently an inpatient
  • Diagnosed with acute myeloid leukemia or acute lymphocytic leukemia
  • Started induction chemotherapy less than 5 days ago
  • Hemoglobin level under 130 g/L at enrollment
Not Eligible

You will not qualify if you...

  • Unable or unwilling to provide informed consent
  • Unwilling to receive blood transfusions
  • Life expectancy less than 72 hours
  • Receiving palliative chemotherapy
  • Requires specialized blood products (e.g., antigen-matched, irradiation)
  • Diagnosed with acute promyelocytic leukemia
  • Diagnosed with hyperleukocytosis (white blood cell count over 100 x 10^9/L)
  • Diagnosed with coagulopathies or currently treated with therapeutic anticoagulants, aspirin, or nonsteroidal anti-inflammatory drugs
  • Evidence of iron overload (ferritin over 800 ng/mL, transferrin saturation over 80%)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Juravinski Hospital

Hamilton, Ontario, Canada, L8V 1C3

Actively Recruiting

Loading map...

Research Team

D

Dimpy Modi

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here